Top

Archives of Gynecology and Obstetrics

Published in:

01-06-2019 | Metastasis | Images in Obstetrics and Gynecology

Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer

Authors: Hongmei Li, Meihua Lv, Baohua Qiao, Xia Li

Published in: Archives of Gynecology and Obstetrics | Issue 6/2019

Abstract

Background

Epithelial ovarian cancer (EOC) is the most common and lethal ovarian cancer which threatens women health. Nowadays, the standard treatment is maximal cytoreductive surgical debulking followed by chemotherapy. However, immunosuppressive environment generated by chemotherapy, which can be reversed by immunotherapy, leads to the failure of standard treatment. Therefore, a combination of chemotherapy and immunotherapy will be a promising strategy for EOC patients.

Method

For in vitro study, CD73 expression, CD73 activity, and CD8⁺ T-cell proliferation were measured after docetaxel (DTXL) treatment with or without CD73 antibody. For in vivo study, tumor growth, tumor weight, and the population of various immune cells in the tumor were analyzed in different drug treatment groups.

Results

DTXL can increase both the CD73 expression and enzymatic activity in patient-derived epithelial cell and ID8 cell while causing immunosuppressive response which was reversed by anti-CD73 antibody (aCD73). Moreover, tumor growth and lung metastasis in mouse were significantly diminished after DTXL + aCD73 treatment.

Conclusion

Blocking CD73/adenosine pathway could reverse the immunosuppression caused by DTXL, and a combination of DTXL with CD73 inhibitor or anti-CD73 antibody would be a more effective and promising therapy for EOC.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14(1):9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084 CrossRefPubMedPubMedCentral

Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ES, Rao VN (2014) Epithelial ovarian cancer: an overview. World J Transl Med 3(1):1–8. https://doi.org/10.5528/wjtm.v3.i1.1 CrossRefPubMedPubMedCentral

Guppy AE, Nathan PD, Rustin GJ (2005) Epithelial ovarian cancer: a review of current management. Clin Oncol (Royal College of Radiologists (Great Britain)) 17(6):399–411CrossRef

Coward JI, Middleton K, Murphy F (2015) New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 7:189–203. https://doi.org/10.2147/ijwh.s52379 CrossRefPubMedPubMedCentral

Kim A, Ueda Y, Naka T, Enomoto T (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res CR 31:14. https://doi.org/10.1186/1756-9966-31-14 CrossRefPubMed

Mittica G, Genta S, Aglietta M, Valabrega G (2016) Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer? Int J Mol Sci. https://doi.org/10.3390/ijms17071169 CrossRefPubMedPubMedCentral

Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M, Kaye S (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87(9):676–681CrossRefPubMed

Cristea M, Han E, Salmon L, Morgan RJ (2010) Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol 2(3):175–187. https://doi.org/10.1177/1758834010361333 CrossRefPubMedPubMedCentral

10.

Katsumata N (2003) Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 89(Suppl 3):S9–s15. https://doi.org/10.1038/sj.bjc.6601495 CrossRefPubMedPubMedCentral

11.

Yvon AM, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10(4):947–959. https://doi.org/10.1091/mbc.10.4.947 CrossRefPubMedPubMedCentral

12.

Lyseng-Williamson KA, Fenton C (2005) Docetaxel: a review of its use in metastatic breast cancer. Drugs 65(17):2513–2531. https://doi.org/10.2165/00003495-200565170-00007 CrossRefPubMed

13.

Wellenstein MD, de Visser KE (2018) Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48(3):399–416. https://doi.org/10.1016/j.immuni.2018.03.004 CrossRefPubMed

14.

Anderson KG, Stromnes IM, Greenberg PD (2017) Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31(3):311–325. https://doi.org/10.1016/j.ccell.2017.02.008 CrossRefPubMedPubMedCentral

15.

Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S (2014) PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 9(2):e89350. https://doi.org/10.1371/journal.pone.0089350 CrossRefPubMedPubMedCentral

16.

Mantia-Smaldone GM, Corr B, Chu CS (2012) Immunotherapy in ovarian cancer. Hum Vaccines Immunother 8(9):1179–1191. https://doi.org/10.4161/hv.20738 CrossRef

17.

Rodriguez GM, Galpin KJC, McCloskey CW, Vanderhyden BC (2018) The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers. https://doi.org/10.3390/cancers10080242 CrossRefPubMedPubMedCentral

18.

Antonioli L, Blandizzi C, Malavasi F, Ferrari D, Hasko G (2016) Anti-CD73 immunotherapy: a viable way to reprogram the tumor microenvironment. Oncoimmunology 5(9):e1216292. https://doi.org/10.1080/2162402x.2016.1216292 CrossRefPubMedPubMedCentral

19.

Leone RD, Emens LA (2018) Targeting adenosine for cancer immunotherapy. J Immunother Cancer 6(1):57. https://doi.org/10.1186/s40425-018-0360-8 CrossRefPubMedPubMedCentral

20.

Zhang B (2010) CD73: a novel target for cancer immunotherapy. Can Res 70(16):6407–6411. https://doi.org/10.1158/0008-5472.can-10-1544 CrossRef

21.

Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ (2016) Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30(3):391–403. https://doi.org/10.1016/j.ccell.2016.06.025 CrossRefPubMed

22.

Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Can Res 70(6):2245–2255. https://doi.org/10.1158/0008-5472.can-09-3109 CrossRef

23.

Theriault BL, Portelance L, Mes-Masson AM, Nachtigal MW (2013) Establishment of primary cultures from ovarian tumor tissue and ascites fluid. Methods Mol Biol (Clifton, NJ) 1049:323–336. https://doi.org/10.1007/978-1-62703-547-7_24 CrossRef

24.

Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Zhang P, Lieberman J, Wang J, Song E (2012) Targeted delivery of PLK1-siRNA by ScFv suppresses Her²⁺ breast cancer growth and metastasis. Sci Transl Med 4(130):130ra148. https://doi.org/10.1126/scitranslmed.3003601 CrossRef

25.

Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 107(46):19997–20002. https://doi.org/10.1073/pnas.1009010107 CrossRefPubMedPubMedCentral

Title: Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer
Authors: Hongmei Li
Meihua Lv
Baohua Qiao
Xia Li
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Published in: Archives of Gynecology and Obstetrics / Issue 6/2019
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05139-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer

Abstract

Background

Method

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2019

Wnt signaling pathway in early- and late-onset preeclampsia: evaluation with Dickkopf-1 and R-Spondin-3 glycoproteins

Modified hysterectomy for placenta increta and percreta: modifications of what?

Pilot study: placental biomarker predictive capability (sFlt-1, PlGF and their ratio) of postpartum maternal outcome

The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial

Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells

Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model